Chitosan nanoparticles for daptomycin delivery in ocular treatment of bacterial endophthalmitis

Drug Delivery

Volumn 22, Issue 7, 2015, Pages 885-893

  Silva, Nádia C ^a   Silva, Sara ^a,b   Sarmento, Bruno ^b,c,d   Pintado, Manuela ^a  

^a UNIVERSIDADE CATÓLICA PORTUGUESA   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c INSTITUTO DE INVESTIGAÇÃO E FORMAÇÃO AVANÇADA EM CIÊNCIAS E TECNOLOGIAS DA SAÚDE   (Portugal)

^d INEB INSTITUTO DE ENGENHARIA BIOMÉDICA   (Portugal)

Author keywords

Antibacterial activity; chitosan; daptomycin; nanoparticles; ocular infection

Indexed keywords

CHITOSAN NANOPARTICLE; DAPTOMYCIN; LYSOZYME; MUCIN; TRIPOLYPHOSPHATE; ANTIINFECTIVE AGENT; CHITOSAN; DRUG CARRIER; NANOPARTICLE; POLYPHOSPHATE; TRIPHOSPHORIC ACID;

ARTICLE; BACTERIAL ENDOPHTHALMITIS; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG RELEASE; DRUG STABILITY; ENDOPHTHALMITIS; GELATION; IN VITRO STUDY; ISOELECTRIC POINT; MINIMUM INHIBITORY CONCENTRATION; MORPHOLOGICAL TRAIT; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PHYSICAL CHEMISTRY; PRIORITY JOURNAL; SCANNING ELECTRON MICROSCOPY; ZETA POTENTIAL; CHEMISTRY; INTRAOCULAR DRUG ADMINISTRATION; MEDICINAL CHEMISTRY; MICROBIAL SENSITIVITY TEST; PROCEDURES;

ADMINISTRATION, OPHTHALMIC; ANTI-BACTERIAL AGENTS; CHEMISTRY, PHARMACEUTICAL; CHITOSAN; DAPTOMYCIN; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; DRUG LIBERATION; ENDOPHTHALMITIS; MICROBIAL SENSITIVITY TESTS; MICROSCOPY, ELECTRON, SCANNING; NANOPARTICLES; PARTICLE SIZE; POLYPHOSPHATES;

EID: 84942930709     PISSN: 10717544     EISSN: 15210464     Source Type: Journal    
DOI: 10.3109/10717544.2013.858195     Document Type: Article

References (45)

1. Agnihotri SA, Mallikarjuna NN, Aminabhavi TM. (2004). Recent advances on chitosan-based micro- and nanoparticles in drug delivery. J Controlled Release 100:5-28.
2. Bayat A, Larijani B, Ahmadian S, et al. (2008). Preparation and characterization of insulin nanoparticles using chitosan and its quartenized derivatives. Nanomedicine 4:115-20.
3. Bihari P, Vippola M, Schultes S, et al. (2008). Optimized dispersion of nanoparticles for biological in vitro and in vivo studies. Part Fibre Toxicol 5:1-14.
4. Bispo PJM, de Melo GB, d'Azevedo PA, et al. (2008). Endoftalmites bacterianas com culturas positivas: uma revisão de 6 anos. Arq Bras Oftalmol 71:617-22.
5. Boonsongrit Y, Mitrevej A, Mueller BW. (2006). Chitosan drug binding by ionic interaction. Eur J Pharm Biopharm 62:267-74.
6. Callegan MC, Engelber M, Parke II DW, et al. (2002). Bacterial endophthalmitis: epidemiology, therapeutics, and bacterium-host interactions. Clin Microbiol Rev 15:111-24.
7. Callegan MC, Gilmore MS, Gregory M, et al. (2007). Bacterial endophthalmitis: therapeutic challenges and host-pathogen interactions. Prog Retin Eye Res 26:189-203.
8. Calvo P, Remuñán-López C, Vila-Jato JL, Alonso MJ. (1997a). Novel hydrophilic chitosan-polyethylene oxide nanoparticles as protein carriers. J Appl Polym Sci 63:125-32.
9. Calvo P, Vila-Jato JL, Alonso MJ. (1997b). Effect of lysozyme on the stability of polyester nanocapsules and nanoparticles: stabilization approaches. Biomaterials 18:1305-10.
10. CLSI. (2005a). Metodologia dos testes de sensibilidade a agentes antimicrobianos por diluição para bactéria de crescimento aeróbico: norma aprovada - Sexta Edição M7-A6. Wayne, PA: Clinical and Laboratory Standards Institute.
11. CLSI. (2005b). Normas de desempenho para testes de sensibilidade antimicrobiana: 15 suplemento informativo M100-S15. Wayne, PA: Clinical and Laboratory Standards Institute.
12. Corfield AP, Carrington SD, Hicks SJ, et al. (1997). Ocular mucins: purification, metabolism and functions. Prog Retin Eye Res 16: 627-56.
13. de Campos AM, Sánchez A, Alonso MJ. (2001). Chitosan nanoparticles: a new vehicle for the improvement of the delivery of drugs to the ocular surface. Application to cyclosporine A. Int J Pharm 224: 159-68.
14. de Campos AM, Diebold Y, Carvalho ELS, et al. (2004). Chitosan nanoparticles as new ocular drug delivery systems. In vitro stability, in vivo fate, and cellular toxicity. Pharm Res 21:803-10.
15. de la Fuente M, Ravinã M, Paolicelli P, et al. (2010). Chitosan-based nanostructures: a delivery platform for ocular therapeutics. Adv Drug Deliv Rev 62:100-17.
16. de Salamanca AE, Diebold Y, Calonge M, et al. (2006). Chitosan nanoparticles as a potential drug delivery system for the ocular surface: toxicity, uptake mechanism and in vivo tolerance. Inves Ophthalmo Vis Sci 47:1416-25.
17. Diebold Y, Calonge M. (2010). Applications of nanoparticles in ophthalmology. Prog Retin Eye Res 29:596-609.
18. Ding S. (1998). Recent developments in ophthalmic drug delivery. Pharm Sci Technolo Today 1:328-35.
19. Du W, Niu S, Xu Y, et al. (2009). Antibacterial activity of chitosan tripolyphosphate nanoparticles loaded with various metal ions. Carbohydr Polym 75:385-9.
20. Dudhani AR, Kosaraju SL. (2010). Bioadhesive chitosan nanoparticles: preparation and characterization. Carbohydr Polym 81:243-51.
21. Enoch DA, Bygott JM, Daly M, Karas A. (2007). Daptomycin. J Infect 55:205-13.
22. Fernandes JC, Tavaria FK, Soares JC, et al. (2008). Antimicrobial effects of chitosans and chitooligosaccharides, upon Staphylococcus aureus and Escherichia coli, in food model systems. Food Microbiol 25: 922-8.
23. Fernández-Urrusuno R, Calvo P, Remuñán-López C, et al. (1999). Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res 16:1576-81.
24. Gan Q, Wang T. (2007). Chitosan nanoparticles as protein delivery carrier - systematic examination of fabrication conditions for efficient loading and release. Colloids Surf B Biointerfaces 59:24-34.
25. Huang X, Du Y, Yuan H, Hu F. (2009). Preparation and pharmacodynamics of low-molecular-weight chitosan nanoparticles containing insulin. Carbohydr Polym 76:368-73.
26. Jeu L, Fung HB. (2004). Daptomycin: a cyclic lipopeptide antimicrobial agent. Clin Ther 26:1728-57.
27. Kinoshita S, Adachi W, Sotozono C, et al. (2001). Characteristics of the human ocular surface epithelium. Prog Retin Eye Res 20:639-73.
28. Kresloff MS, Castellari AA, Zarbin MA. (1998). Endophthalmitis. Surv Ophthalmol 43:193-224.
29. Martens-Lobenhoffer J, Kielstein JT, Oye C, Bode-Böger SM. (2008). Validated high performance liquid chromatography-UV detection method for the determination of daptomycin in human plasma. J Chromatogr B 875:546-50.
30. Mehravar R, Jahanshahi M, Saghatoleslami N. (2009). Production of biological nanoparticles from a-lactalbumin for drug delivery and food science application. Afr J Biotechnol 8:6822-7.
31. Motwani SK, Chopra S, Talegaonkar S, et al. (2008). Chitosan-sodium alginate nanoparticles as submicroscopic reservoirs for ocular delivery: formulation, optimization and in vitro characterization. Eur J Pharm Biopharm 68:513-25.
32. Mourya VK, Inamdar NN. (2008). Chitosan-modifications and applications: opportunities galore. React Funct Polym 68:1013-51.
33. Nagpal K, Singh SK, Mishra, DN. (2010). Chitosan nanoparticles: a promising system in novel drug delivery. Chem Pharm Bull 58: 1423-30.
34. Nanjawade BK, Manvi FV, Manjappa AS. (2007). In situ-forming hydrogels for sustained ophthalmic drug delivery. J Control Release 122:119-34.
35. Pan Y, Li Y, Zhao H, Zheng J, et al. (2002). Bioadhesive polysaccharide in protein delivery system: chitosan nanoparticles improve the intestinal absorption of insulin in vivo. Int J Pharm 249:139-47.
36. Qi L, Xu Z, Jiang X, et al. (2004). Preparation and antibacterial activity of chitosan nanoparticles. Carbohydr Res 339:2693-700.
37. Reis CP, Neufeld RJ, Ribeiro AJ, Veiga F. (2006). Nanoencapsulation I: methods for preparations of drug-loaded polymeric nanoparticles. Nanomedicine 2:8-21.
38. Rhoades J, Roller S. (2000). Antimicrobial actions of degraded and native chitosan against spoilage organisms in laboratory media and foods. Appl Environl Microbiol 66:80-6.
39. Robbel L, Marahiel MA. (2010). Daptomycin, a bacterial lipopeptide synthesized by a nonribosomal machinery. J Biol Chem 285:27501-8.
40. Romero CF, Rai K, Lowder CY, Adal KA. (1999). Endogenous endophthalmitis: case report and brief review. Am Fam Physician 60:510-14.
41. Severino P, Vasconcellos FC, Figueiredo ES. (2007). Uso tópico de quitosana em oftalmologia. Rev Bras Farm 88:155-8.
42. Subramanian A, Vasanthan KS, Krishnan UM, Sethuraman S. (2011). Chitosan and its derivatives in clinical use and applications. In: Domb AJ, Kumar N, Ezra A, eds. Biodegradable polymers in clinical use and clinical development. New Jersey, USA: John Wiley & Sons, Inc, 113-35.
43. Thorne GM, Alder J. (2002). Daptomycin: a novel lipopeptide antibiotic. Clin Microbiol Newslett 24:33-40.
44. Xu Y, Du Y. (2003). Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. Int J Pharm 250:215-26.
45. Zarbin MA, Montemagno C, Leary JF, Ritch R. (2010). Nanomedicine in ophthalmology: the new frontier. Am J Ophthalmol 150:144-62.